Myomo Inc. (NYSE American: MYO) appointed William Febbo as a director effective April 14, 2026, to serve until the 2028 annual meeting of stockholders, according to a company statement. The appointment brings Myomo's board to six directors.

Febbo currently serves as chief executive officer and director of Performance Health Systems, a privately-held company he joined in February 2026. He previously served as CEO of OptimizeRx Corporation (NASDAQ: OPRX) from 2015 to 2024, where the company's revenue grew from $5 million to $92 million.

"We are pleased to welcome Will to our Board of Directors," said Paul Gudonis, chairman and CEO of Myomo. "I'm looking forward to Will's contributions, particularly his expertise in scaling innovative direct-to-patient healthcare solutions which is a key piece of strategy for 2026 and beyond."

During Febbo's tenure at OptimizeRx, he led the company's transition from a single point-of-care product provider into what the company describes as an AI-driven omnichannel platform. He also guided OptimizeRx's uplisting from over-the-counter to Nasdaq trading.

Febbo has co-founded and led companies in capital markets, including Merriman Holdings Inc. and Digital Capital Network. He holds a bachelor's degree in international studies and Spanish from Dickinson College and serves as an MIT-affiliated faculty member in the linQ program.

Myomo develops the MyoPro product line, which the company describes as a powered upper-limb orthosis designed to support arms and restore function for patients with neurological disorders and upper-limb paralysis. The Burlington, Massachusetts-based company markets its devices to patients suffering from stroke, brachial plexus injury, traumatic brain or spinal cord injury.